COMMUNIQUÉS West-GlobeNewswire

Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection
09/11/2018
- Oncolytic virus enhances immune checkpoint inhibitor response in prostate cancers - CALGARY, Alberta and SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently [...]
Neos Therapeutics Reports Third Quarter 2018 Financial Results
09/11/2018
Company to host conference call today at 8:30am ET DALLAS and FORT WORTH, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical company focused on developing [...]
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
09/11/2018
--CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies in Immuno-Oncology-- ZUG, Switzerland and CAMBRIDGE, Mass. and GAITHERSBURG, Md., Nov. [...]
VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update
09/11/2018
-- Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively -- -- Encouraging early immunologic data observed in Phase 1/2a study of VBI-1901 for the treatment of [...]
Antares Pharma Announces Data Presentation at the 2018 Sexual Medicine Society Scientific Annual Meeting
09/11/2018
XYOSTED™ AMBULATORY BLOOD PRESURE ABSTRACT HAS BEEN SELECTED FOR POSTER PRESENTATION EWING, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from the 26-week Phase 3 [...]
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
09/11/2018
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3 interim analysis [...]
Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress
09/11/2018
LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat [...]
PLx Pharma Inc. Reports Third Quarter 2018 Results
09/11/2018
PLx has identified the alternate supply of a key ingredient for Vazalore HOUSTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company [...]
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference 2018
09/11/2018
RANCHO CUCAMONGA, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO will be presenting at the Jefferies London [...]
Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions
09/11/2018
NEW YORK and MELBOURNE, Australia, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its allogeneic mesenchymal [...]
RadNet Reports Third Quarter Financial Results and Reaffirms Previously Announced 2018 Guidance Levels
09/11/2018
Total Net Revenue (“Revenue”) increased 6.4% to $242.1 million in the third quarter of 2018 from $227.6 million in the third quarter of 2017 Adjusted EBITDA (1) increased 5.5% to $38.1 million in the third quarter of [...]
NASH clinical trial presentation and continued revenue growth
09/11/2018
Key Highlights: Professor Arun Sanyal to present IMM-124E NASH clinical trial results at the Liver Meeting in San Francisco Travelan® on display at HealthEd Australian Travelan® sales continue to grow, with a Q1 CY19 [...]
AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases
09/11/2018
Increasing evidence points to Abeta oligomers as the toxic species in AD, and likely linked to Tau pathology and neuroinflammation. Immunotherapies and small molecule anti-Tau therapeutics hold much promise in treating [...]
Rule 2.9 Announcement
09/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 9 November 2018 [...]
Bavarian Nordic Announces Interim Results for the First Nine Months of 2018
09/11/2018
COPENHAGEN, Denmark, November 9, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results in line with guidance for the first nine months of 2018 and business progress for the [...]
Nine-month interim report (Q3) 2018
09/11/2018
Better than expected performance continued in Q3 (unaudited) Financial results in Q3 were again better than expected and the full-year outlook has been updated accordingly. Execution of ALK’s growth strategy saw good [...]
DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting
09/11/2018
Montrouge, France, November 9, 2018 DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting Three abstracts on Viaskin [...]
DBV Technologies présentera des données soutenant l'utilisation de l'immunothérapie épicutanée pour le traitement de l'allergie à l'arachide à l'ACAAI 2018
09/11/2018
Montrouge, France, le 9 novembre (07h30 CEST), 2018 DBV Technologies présentera des données soutenant l'utilisation de l'immunothérapie épicutanée pour le traitement de l'allergie à l'arachide à l'ACAAI 2018 Trois [...]
ESPERITE (ESP) expects publication of Annual Report 2017 before 17 November 2018
09/11/2018
Amsterdam, The Netherlands - 09 November 2018 Esperite announces that the preparation of its Annual Report 2017 is nearly finalized and expects the publication of its Annual Report 2017 before 17 November 2018. About [...]

Pages